Maternal care for anti-D [Rh] antibodies, second trimester (fetus 2)
ICD-10 O36.0122 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, second trimester (fetus 2).
O36.0122 refers to maternal care for a pregnancy complicated by the presence of anti-D (Rh) antibodies during the second trimester, specifically for the second fetus in a multiple gestation. This condition arises when an Rh-negative mother carries an Rh-positive fetus, leading to the potential for hemolytic disease of the newborn (HDN). The presence of these antibodies can cause fetal complications such as anemia, jaundice, and in severe cases, fetal distress or intrauterine growth restriction (IUGR). Monitoring and management strategies include regular ultrasound assessments to evaluate fetal growth and well-being, as well as possible interventions like intrauterine transfusions if significant anemia is detected. Maternal care involves close observation and may require collaboration with maternal-fetal medicine specialists to ensure optimal outcomes for both mother and fetus.
Detailed records of maternal antibody status, fetal assessments, and any interventions performed.
Management of a pregnant patient with known Rh sensitization and monitoring for fetal anemia.
Ensure accurate coding of multiple gestations and individual fetal assessments.
Comprehensive documentation of high-risk pregnancy management, including ultrasound findings and treatment plans.
Complex cases involving intrauterine transfusions or other interventions for fetal anemia.
Focus on the multidisciplinary approach to managing high-risk pregnancies.
Used for monitoring fetal growth and well-being in pregnancies complicated by anti-D antibodies.
Document indications for ultrasound and findings related to fetal health.
Obstetricians should ensure that ultrasound findings are clearly linked to maternal conditions.
Anti-D antibodies can lead to serious fetal complications, including hemolytic disease of the newborn. It is crucial to monitor pregnancies affected by these antibodies closely to ensure timely interventions and optimal outcomes.
